U.S. FDA approves Alexion Pharma's blood disorder drug
(Reuters) – The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc’s blood disorder drug Ultomiris, the pharma regulator’s website showed on Friday. The drug aims to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells divide prematurely. Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila… Read More »